[Form 4] Blend Labs, Inc. Insider Trading Activity
Blend Labs insider sale reported. Director Eric H. Woersching sold 20,000 shares of Class A common stock on 09/05/2025 at $4.005 per share under a Rule 10b5-1 trading plan adopted March 4, 2025. After the reported sale he beneficially owns 30,000 shares. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/09/2025. The filing discloses the sale was executed pursuant to an established written plan; no other transactions, grants, or derivative positions are listed.
- None.
- Director sold 20,000 shares of Class A common stock, reducing beneficial ownership to 30,000 shares
- Sale price $4.005 per share, which may signal liquidity-taking by insider (document shows disposition only)
Insights
TL;DR: Director executed a planned sale of a modest holding; limited direct impact on company fundamentals.
The reported sale of 20,000 Class A shares at $4.005 reduces the director's direct stake to 30,000 shares. Because the transaction was made under a Rule 10b5-1 plan, it appears pre-scheduled rather than opportunistic. The size of the sale relative to company float is not stated in the filing, so materiality for valuation is unclear from this document alone. No options, grants, or purchases are reported, which limits interpretation to a straightforward disposition.
TL;DR: Use of a 10b5-1 plan suggests compliance with insider trading controls; disclosure is routine.
The filing documents compliance with Section 16 reporting via a Form 4 and explicitly cites a Rule 10b5-1 trading plan adopted March 4, 2025, which provides an affirmative defense to insider trading allegations. The signature by an attorney-in-fact is properly indicated. From a governance perspective, the disclosure is complete for this transaction; however, broader governance implications require examining aggregate insider activity and timing relative to material company events, which this form does not provide.